Lixte Biotechnology Holdings Accounts Payables 2011-2026 | LIXT

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Quarterly Accounts Payables Lixte Biotechnology Holdings

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	45 K	47 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
47 K	45 K	46 K

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	3.46 M	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	1.93 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Akouos AKUS	1.28 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
I-Mab IMAB	570 M	-	-	$ 866 M	China
Amarin Corporation plc AMRN	45.4 M	$ 14.67	-0.07 %	$ 6.09 B	Irlanda
Albireo Pharma ALBO	6.52 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	3.98 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	724 K	-	-39.0 %	$ 4.57 M	USA
Arena Pharmaceuticals ARNA	13.3 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	155 K	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Atreca BCEL	1.74 M	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	18.5 M	-	-	$ 546 M	USA
Acasti Pharma ACST	601 K	-	4.01 %	$ 150 M	Canada
Cabaletta Bio CABA	6.64 M	$ 2.82	1.44 %	$ 283 M	USA
Avid Bioservices CDMO	20.7 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	1.61 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	3.81 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	1.97 M	$ 1.29	-3.01 %	$ 329 M	Britain
CEL-SCI Corporation CVM	1.45 M	$ 3.47	-1.7 %	$ 221 M	USA
BeiGene, Ltd. BGNE	479 M	-	0.49 %	$ 251 B	Cayman-islands
Denali Therapeutics DNLI	11.1 M	$ 19.74	-12.17 %	$ 3.25 B	USA
BioDelivery Sciences International BDSI	8.11 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	11.6 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	6.75 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	463 K	$ 1.09	-9.17 %	$ 22.4 M	Israel
Enochian Biosciences ENOB	12.6 M	-	-	$ 40.5 M	USA
Equillium EQ	755 K	$ 2.06	-	$ 118 M	USA
Esperion Therapeutics ESPR	65.1 M	$ 2.85	3.26 %	$ 592 M	USA
Eton Pharmaceuticals ETON	11 M	$ 23.45	-1.64 %	$ 631 M	USA
China SXT Pharmaceuticals SXTC	1.16 M	$ 1.32	-5.2 %	$ 1.88 M	China
Bellerophon Therapeutics BLPH	1.23 M	-	-74.18 %	$ 955 K	USA
CRISPR Therapeutics AG CRSP	11.1 M	$ 47.55	0.98 %	$ 4.28 B	Schweiz
Arbutus Biopharma Corporation ABUS	1.17 M	$ 4.45	-1.77 %	$ 853 M	Canada
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA